The man who turned Vitaminwater and BodyArmor into household beverage names is turning his attention to the sneaker industry.
Continue readingCategory Archives: Uncategorized
Netflix stock sinks as Wall Street looks for clarity on revenue growth
The selloff in Netflix shares follows a 60% year-to-date rally, spurred by the roll out its cheaper, ad-supported plan and a crackdown on password sharing.
Continue readingJune home sales drop to the slowest pace in 14 years as short supply chokes the market
June home sales declined 18.9% compared with last year. That’s the slowest sales pace for June since 2009.
Continue readingVictims want Morgan Stanley to answer for ex-financial advisor’s Ponzi scheme
Victims filed arbitration claims against Morgan Stanley, alleging that it failed to reasonably supervise its employee.
Continue readingWalmart cuts price of Walmart+ for households that receive food stamps, other government aid
Walmart is trying to grow its Walmart+ membership base and has noticed more price sensitivity among shoppers.
Continue readingKenvue earnings top estimates in J&J spinoff’s first quarterly report since IPO
J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff’s business for the time being.
Continue readingAmerican Airlines raises 2023 profit forecast after strong second quarter
Record revenue of $14.06 billion topped analysts’ expectations and was up 4.7% from a year earlier.
Continue readingJohnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
The results come amid investor anxiety over the thousands of lawsuits claiming that J&J’s talc-based baby powder and other products caused cancer.
Continue readingNetflix earnings showcase strength as the rest of the media industry struggles
Netflix’s core business continues to chug along as the rest of the media and entertainment industry searches for new growth.
Continue readingPfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
Pfizer is among several drugmakers racing to develop the world’s first shot targeting Group B strep disease, which kills thousands of infants each year.
Continue reading